Company intelligence / Profile preview

Ainos, Inc.

San Diego, California, United Statesainos.com ↗

Ownership: Public · AIMD
Employees: ~44
Development stage: Commercial

Overview

Developing AI-powered point-of-care testing solutions and low-dose interferon therapeutics. Has commercialized products including SARS-CoV-2 Antigen Rapid Test Kit and VELDONA Pet health supplements.

Therapeutic areas: HematologyImmunologyRare DiseasesInfectious Diseases
Modalities: Low-dose interferon therapeuticsSynthetic RNA
Industry: Biotech

Drug pipeline

1 asset

veldona

Unknown

Partnerships

Advanced Semiconductor Engineering, Inc. (ASE)National Health Research Institutes (Taiwan)

Financials

Market cap: $10.9M
Total revenue: $152
Enterprise value: $23.3M

Beyond the preview

Go deeper on Ainos, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ainos, Inc..

Explore the full profile